Summary of Significant Accounting Policies (Narrative) (Details) (USD $)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2012
Significant Accounting Policies [Line Items]
Revenue from pharmaceutical clients	$ 2,441,693	$ 1,029,842
Receivable Balance	5,269,551		5,373,023
Accounts receivable, allowance for doubtful accounts	1,048,864		991,990
Bad debt expense	468,463	255,925
Amortization period of software development costs	5 years
Line of credit, expiration date	Mar. 07, 2015
Line of credit, fee for unused portion	0.25%	0.375%
Line of credit, minimum quick ratio	1.5
Line of credit, maximum borrowing capacity	2,000,000
Line of credit, borrowing base percentage of pharmaceutical accounts receivable	80.00%
Line of credit, interest above prime rate	1.00%
Line of credit, interest charged	5.00%
Line of credit, amount drawn	1,000,000		1,000,000
Recognized interest and penalties	107	0
Required minimum bank balance	4,000,000
Advertising costs	0	8,881
Uninsured foreign cash balance	7,236
University of Southern California [Member]
Significant Accounting Policies [Line Items]
Royalties expensed in cost of revenue	104,105	56,502
Roche Molecular Systems [Member]
Significant Accounting Policies [Line Items]
Royalties expensed in cost of revenue	90,145	63,468
Cost of Goods, Total [Member] | Supplier Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Concentration risk percentage	65.00%	68.00%
Letter of Credit [Member]
Significant Accounting Policies [Line Items]
Line of credit, maximum borrowing capacity	500,000
Clinical [Member]
Significant Accounting Policies [Line Items]
Payment period from the date of invoice	45 days
Receivable Balance	1,917,601		2,549,665
ResponseDX [Member]
Significant Accounting Policies [Line Items]
Receivable Balance	3,351,950		2,823,358
Accounts receivable, allowance for doubtful accounts	1,048,864		991,990
Bad debt expense	$ 468,463	$ 178,065